Is white blood cell reduction equivalent to antibody screening in preventing transmission of cytomegalovirus by transfusion? A review of the literature and meta-analysis

Transfusion Medicine Reviews

Volumn 19, Issue 3, 2005, Pages 181-199

  Vamvakas, Eleftherios C ^a,b  

^a CANADIAN BLOOD SERVICES   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY SCREENING; BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; CENTRIFUGATION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; HUMAN; LEUKOCYTE; NONHUMAN; REVIEW; RISK ASSESSMENT; RISK REDUCTION; VIRUS TRANSMISSION;

EID: 21744440719     PISSN: 08877963     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tmrv.2005.02.002     Document Type: Article

References (56)

1. S. MacKinnon, A.K. Burnett, and R.J. Crawford Seronegative blood products prevent primary cytomegalovirus infection after bone marrow transplantation J. Clin. Pathol. 41 1988 948 950
2. W.J. Miller, J. McCullough, and H.H. Balfour Jr. Prevention of cytomegalovirus-infection following bone marrow transplantation: A randomized trial of blood product screening Bone Marrow Transplant. 7 1991 227 234
3. M.T. Brady, J.D. Milam, and D.C. Anderson Use of deglycerolized red blood cells to prevent posttransfusion infection with cytomegalovirus in neonates J. Infect. Dis. 150 1984 334 339
4. R.A. Bowden, S.J. Slichter, and M.H. Sayers Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant Blood 79 1991 246 250
5. R.A. Bowden, S.J. Slichter, and M.H. Sayers A comparison of filtered leukocyte reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant Blood 86 1995 3598 3606
6. W.G. Nichols, T.H. Price, and T. Gooley Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products Blood 101 2003 4195 4200
7. M.A. Blajchman, M. Goldman, and J.F. Freedman Proceedings of a consensus conference: Prevention of post-transfusion CMV in the era of universal leukoreduction Transfus. Med. Rev. 15 2001 1 20
8. A. Laupacis, J. Brown, and B. Costello Prevention of post-transfusion CMV in the era of universal leukoreduction: A consensus statement Transfusion 41 2001 560 569
9. International Forum Prevention of post-transfusion cytomegalovirus: Leukoreduction or screening? Vox Sang. 83 2002 72 87
10. D.M. Smith Jr. Leukocyte reduction for the prevention of transfusion-transmitted cytomegalovirus (TT-CMV) Association Bulletin #97-2 1997 American Association of Blood Banks Bethesda, MD
11. D. Malloy, and K.S. Lipton Update on provision of CMV-reduced-risk cellular blood components Association Bulletin #02-4 2002 American Association of Blood Banks Bethesda, MD
12. D.H. Pamphilon, J.R. Rider, and J.A.J. Barbara Prevention of transfusion-transmitted cytomegalovirus infection Transfus. Med. 9 1999 115 123
13. C.D. Hillyer, K.V. Lankford, and J.D. Roback Transfusion of the HIV-seropositive patient: Immunomodulation viral reactivation, and limiting exposure to EBV (HHV-4), CMV (HHV-5), and HHV-6, 7, and 8 Transfus. Med. Rev. 13 1999 1 17
14. J.K. Preiksaitis The cytomegalovirus-"safe" blood product: Is leukoreduction equivalent to antibody screening? Transfus. Med. Rev. 14 2000 112 136
15. E.M. Landaw, M. Kanter, and L.D. Petz Safety of filtered leukocyte-reduced blood products for prevention of transfusion-associated cytomegalovirus infection Blood 87 1996 4910
16. R. Der-Simonian, and N. Laird Meta-analysis in clinical trials Control. Clin. Trials 7 1986 177 188
17. H. Cooper L.V. Hedges The handbook of research synthesis 1994 Russell Sage Foundation New York, NY 289 291
18. T. Luthardt, H. Siebert, and I. Lösel Cytomegalovirus-infektionen bei Kindern mit Blutaustausch-transfusion im Neugeborenenalter Klin. Wochenschr. 49 1971 81 86
19. A. Kumar, G.A. Nankervis, and R.A. Cooper Acquisition of cytomegalovirus infection in infants following exchange transfusion: A prospective study Transfusion 20 1980 327 331
20. A.S. Yeager, F.C. Grumet, and E.B. Hafleigh Prevention of transfusion-acquired cytomegalovirus infections in newborn infants J. Pediatr. 98 1981 281 287
21. J.K. Preiksaitis, S. Rosno, and C. Grumet Infections due to herpes viruses in cardiac transplant recipients: Role of the donor heart and immunosuppressive therapy J. Infect. Dis. 147 1983 974 981
22. R.A. Bowden, M. Sayers, and N. Flournoy Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation N. Engl. J. Med. 314 1986 1006 1010
23. J.K. Preiksaitis, S. Desai, and W. Vaudry Transfusion- and community-acquired cytomegalovirus infection in children with malignant disease: A prospective study Transfusion 37 1997 941 946
24. L.F. Verdonck, Y.C. De Graan-Hentzen, and A.W. Dekker Cytomegalovirus seronegative platelets and leukocyte poor red blood cells can prevent primary cytomegalovirus infection after bone marrow transplantation Bone Marrow Transplant. 2 1987 73 78
25. D.H. Pamphilon, A.B.M. Foot, and A. Adeodu Prophylaxis and prevention of CMV infection in BM allograft recipients: Leukodepleted platelets are equivalent to those from CMV-seronegative donors Bone Marrow Transplant. 23 1999 S66 (Suppl 1)
26. J.K. Preiksaitis Indications for the use of cytomegalovirus-seronegative blood products Transfus. Med. Rev. 5 1991 1 17
27. G.E. Tegtmeier Posttransfusion cytomegalovirus infections Arch. Pathol. Lab. Med. 113 1989 236 245
28. G.J. Demmler, M.T. Brady, and H. Bijou Posttransfusion cytomegalovirus infection in neonates: Role of saline-washed red blood cells J. Pediatr. 108 1986 762 765
29. N.L.C. Luban, A.E. Williams, and M.G. MacDonald Low incidence of acquired cytomegalovirus infection in neonates transfused with washed red blood cells Am. J. Dis. Child. 141 1987 416 419
30. B.J. Taylor, R.F. Jacobs, and R.L. Baker Frozen deglycerolyzed blood prevents transfusion-acquired cytomegalovirus infections in neonates Pediatr. Infect. Dis. 5 1986 188 191
31. N.E. Tolkoff-Rubin, R.H. Rubin, and E.E. Keller Cytomegalovirus infection in dialysis patients and personnel Ann. Intern. Med. 89 1978 625 628
32. T.L. Simon, J.D. Johnson, and H. Koffler Impact of previously frozen deglycerolized red blood cells on cytomegalovirus transmission to newborn infants Plasma Therapy 8 1987 51 56
33. W.H. Dzik Leukoreduction of blood components Curr. Opin. Hematol. 9 2002 521 526
34. L.J. Dumont, W.H. Dzik, and P. Rebulla Practical guidelines for process validation and process control of white-cell-reduced blood components: Report of the Biomedical Excellence for Safer Transfusion (BEST) Working Party of the International Society of Blood Transfusion (ISBT) Transfusion 36 1996 11 20
35. M.F. Murphy, P.C. Grint, and A.E. Hardiman Use of leukocyte-poor blood components to prevent primary cytomegalovirus (CMV) infection in patients with acute leukemia Br. J. Haematol. 70 1988 253 254
36. G.L. Gilbert, K. Hayes, and I.L. Hudson Prevention of transfusion-acquired cytomegalovirus infection in infants by blood filtration to remove leukocytes. Neonatal Cytomegalovirus Infection Study Group Lancet 1 1989 1228 1231
37. H. Ohto, N. Ujiie, and H. Hirai Lack of difference in cytomegalovirus transmissions via the transfusion of filtered-irradiated and nonfiltered-irradiated blood to newborn infants in an endemic area Transfusion 39 1999 201 205
38. Y.C.E. De Graan-Hentzen, and J.W. Gratama Prevention of primary cytomegalovirus infection in patients with hematologic malignancy by intensive white cell depletion of blood products Transfusion 29 1989 757 760
39. R.A. Bowden, M.H. Sayers, and M. Cays The role of blood product filtration in the prevention of transfusion-associated cytomegalovirus (CMV) infection after marrow transplant Transfusion 29 1989 57S (Suppl 1)
40. T. DeWitte, A. Schattenberg, and B.A. Van Dijk Prevention of primary cytomegalovirus infection after allogeneic bone marrow transplantation by using leukocyte-poor random blood products from cytomegalovirus unscreened blood bank donors Transplantation 50 1990 964 968
41. L. Eisenfeld, H. Silver, and J. McLaughlin Prevention of transfusion-associated cytomegalovirus infection in neonatal patients by the removal of white cells from blood Transfusion 32 1992 205 209
42. H.C. Van Prooijen, J.J. Visser, and W.R. van Oostendorp Prevention of primary transfusion-associated CMV infection after marrow transplant recipients by the removal of white cells from blood components with high affinity filters Br. J. Haematol. 87 1994 144 147
43. A.B. Narvios, D. Przepiorka, and J. Tarrand Transfusion support using filtered unscreened blood products for cytomegalovirus-negative allogeneic marrow transplant recipients Bone Marrow Transplant. 22 1998 575 577
44. N.L. Luban, and C. Manno Lack of difference in CMV transmission via the transfusion of filtered irradiated and nonfiltered irradiated blood to newborn infants in an endemic area Transfusion 40 2000 387 389
45. W.E. Rawls, C.L. Wong, and M. Blajchman Neonatal cytomegalovirus infections: The relative role of neonatal blood transfusion and maternal exposure Clin. Invest. Med. 7 1984 13 19
46. G.E. Tegtmeier Transfusion-acquired cytomegalovirus infection: Approaching resolution J.V. Linden C. Bianco Blood safety and surveillance 2001 Marcel Dekker Inc. New York, NY 315 333
47. F. Zhanghellini, S.B. Boppana, and V.C. Emery Asymptomatic primary cytomegalovirus infection: Virologic and immunologic features J. Infect. Dis. 180 1999 702 707
48. J.L. Waner, T.H. Weller, and S.V. Kevy Patterns of cytomegalovirus complement fixing antibody activity: A longitudinal study of blood donors J. Infect. Dis. 127 1973 538 543
49. D.J. James, S. Sikotra, and M. Sivakumaran The presence of free infectious cytomegalovirus (CMV) in the plasma of donated CMV-seropositive blood and platelets Transfus. Med. 7 1997 123 126
50. M.R. Adams, D.M. Fisher, and L.J. Dumont Detecting failed WBC-reduction processes: Computer simulations of intermittent and continuous process failure Transfusion 40 2000 1427 1433
51. L.J. Dumont Statistical process validation of leukoreduced blood components. International Forum: UK Transfus. Sci. 19 1998 35 37
52. Guidance for Industry Pre-storage leukocyte reduction of whole blood and blood components intended for transfusion. Draft 2001 Food and Drug Administration Rockville, MD
53. A. Ratko, J.P. Cummings, and H. Oberman Evidence-based recommendations for the use of WBC-reduced cellular blood components Transfusion 41 2001 1310 1319
54. M.L. Landry, D. Ferguson, and T. Stevens-Ayers Evaluation of CMV Brite kit for detection of cytomegalovirus pp65 antigenemia in peripheral blood leukocytes by immunofluorescence J Clin. Microbiol. 34 1996 1337 1339
55. M. Boeckh, R.A. Bowden, and T. Gooley Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients Blood 93 1999 1781 1782
56. D.B. Petiti Meta-analysis, decision analysis, and cost-effectiveness analysis: Methods for quantitative synthesis in medicine 2nd ed. 2000 Oxford University Press New York, NY